Bharat Biotech Seeks DCGI’s Permission To Extend Shelf Life Of Covid-19 Vaccine 'COVAXIN'

The Hyderabad-based firm, which was earlier given permission for sale and distribution of Covaxin with shelf life of six months when stored at two to eight degrees Celsius, has in support of its proposal submitted updated accelerated and real-time stability data of Covaxin along with the justification for the extension of shelf-life, PTI reported sources as saying.

Covaxin

New Delhi: Bharat Biotech has written to the Drugs Controller General of India (DCGI) seeking extension of the shelf-life of its indigenously developed Covid-19 vaccine Covaxin from six to 24 months.

The Hyderabad-based firm, which was earlier given permission for sale and distribution of Covaxin with shelf life of six months when stored at two to eight degrees Celsius, has in support of its proposal submitted updated accelerated and real-time stability data of Covaxin along with the justification for the extension of shelf-life, PTI reported sources as saying.

READ: Prices Of Covaxin, Covishield Announced As India Gears Up For Smooth Covid Vaccination From May 1

“Now, we are herewith applying for the extension of shelf life from six months to 24 months when stored at 2-8 degrees Celsius,” Bharat Biotech said in its application to India’s drug regulator.

Covaxin and the Serum Institute of India manufactured Covishield are the two vaccines being used in the country’s current vaccination drive as India battles the Covid-19 pandemic.

READ: Major Ports Waive-Off All Charges For Ships Carrying Oxygen & Related Equipment Cargo Amid Covid Crisis

Earlier in February, India’s drug regulator had extended Covishield’s shelf-life from six to nine months from its manufacturing date.